New cancer pill shows promise in early trial

NCT ID NCT04991480

Completed Disease control Sponsor: Artios Pharma Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new oral drug called ART4215 in 93 people with advanced or metastatic solid tumors, including breast cancer. The main goals were to find a safe dose and check for side effects when given alone or with other cancer drugs (talazoparib or niraparib). Researchers also looked at whether the drug could slow tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ART4215 (a DNA repair blocker, taken as a pill)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors, especially those with breast cancer.
What could go wrong: This is an early Phase 1/2a trial with only 93 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cancer Her2-receptor negative breast cancer metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER BREAST CANCER METASTATIC CANCER

Contacts and locations

Locations

Florida Cancer Specialists

Orlando, Florida, 32827, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Oklahoma University

Oklahoma City, Oklahoma, 73104, United States
Sarah Cannon Research Institute

London, England, UK/W1G 6AD, United Kingdom
Tennessee Oncology

Nashville, Tennessee, 37203, United States
University of Pennsylvania/Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States
Yale School of Medicine

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.